Dat Xanh (HSX: DXG) sets total revenue and profit targets in 2020 of VND4.9tn (-16% YoY) and VND1.0tn (-15% YoY), respectively. Management has a prudent view due to the impact of the Covid-19 being highly unpredictable. Generally, this profit guidance is in line with our forecast, with revenue and NPAT-MI of VND5.5tn and VND1.0tn.
After a rough 2019, FRT is expected to have a tougher 2020 before recovering from 2021 on. The covid-19 pandemic is impacting consumer spending and retailing footfall. The saturated smartphone market will further hurt FPT Shop sales. Meanwhile, bad-debt of F-Friend and F-Subsidy is still a concern and FRT will need to write of VND 15bn more in 2020. On the other hand, Long Chau Pharmacy is still in an expansion phase but as yet to contribute to profits
For IMP, business prospects come mainly from the ETC channel (hospitals), considering that the OTC channel (pharmacies) is stacked with competition and is not a huge market either (only 25% of total drug sales in Vietnam). On the other hand, ETC channel offers a lot of potential for EU-GMP standard manufacturers to replace foreign medicines in the Tier 1 and 2 bid. Policy wise, Circular 15/2019 was really a big catalyst for the like of IMP
In 2Q2020, BFC targets to consume 191 thousand tons of NPK, down 6% YoY. Revenue and EBT respectively are set at VND1,796bn and VND52bn. We believe that the actual number in 2Q should be higher than the plan
NKG’s operating performance improved strongly as net income increased from VND -101.6 billion in 1Q2019 to VND 41.5 billion in 1Q2020. Its gross margin rose noticeably from 0.0% in 1Q2019 to 8.6% in 1Q2020. NKG’s net income and gross margin were supported by a strong rise in HRC prices, which increased significantly to USD 520/ton in 1Q2020 after hitting a bottom at USD 420/ton in 4Q2019. However, its net income was hit by a foreign exchange loss of VND 35 billion, caused by a surge of roughly 1.7% in the USD/VND exchange rate.
More and more predictions coming from so-called ‘experts’ that the world is heading for a debt deflation of the type last seen in the Great Depression of 1929-30. This writer is not naturally unsympathetic to such views. We believe that the extraordinary policy responses to Covid-19 marks the beginning of the end of the disinflationary era in existence since the early 1980s.
In 4M2020, MWG recorded consolidated revenue of VND 37,187 bn (+9% YoY) and consolidated NPAT of VND 1,314 bn (-6% YoY). For April-2020, MWG posted revenue of VND 7,834 (-14% YoY) and NPAT of VND 208 bn (-45% YoY), respectively. The decline is mostly due to a -30% YoY drop in revenue of TGDD & DMX. At the beginning of April, the company temporarily closed over 600 TGDD & DMX stores, which are mostly in the North, to comply with Government’s social-lockdown directive. We also see that open store incurred 30% revenue losses due to sluggish retail footfall. As of April 23rd, the company has reopened most of the closed stores. Despite weakness in TGDD+DMX, BHX continued to record impressive revenue of VND 1,462 bn (+142% YoY) in April-2020, thus helped lifting consolidated revenue. However, consolidated NPAT declined significantly as BHX is still in an expansion phase and has yet to deliver profit. |
TCB achieved a good 1Q business performance as the impact of Covid-19 has yet to be reflected fully. Results in the next quarters are expected to be hit harder. Set aside the concentration risk of lending to real estate-related sectors, we appreciate the bank’s solid balance sheet, with a focus on lower risk segments, such as high-income group, working capital and collateralization. A significant portion of 1Q earnings was also spent to accumulate more room for NPL and LLR, in precaution for probable bad debt formation upon the outbreak. Considering the current stable condition of the real estate market, we think TCB would show a strong resilience to this crisis and would be able to recover strongly whence the pandemic impact is over.
We forecast TCB’s earnings growth to reach 14.4% YoY in 2020E, before recovering to c.25% YoY in 2021E. We keep our target price at VND 24,000, equivalent to a potential upside of 14% versus the current market price. We thereby recommend to ACCUMULATE the stock.
The performance of the main segment, pangasius, appeared to be better than our expectations for 2Q2020. Although the collagen-gelatin (C-G) expansion plan will be completed later than previously planned, the management believes that the company’s adjustments in operation and the positive market demand for collagen could guarantee the revenue and PAT target of this segment. The new project of fish oil for human consumption will also contribute in improving profit margin. However, although the selling price of pangasius has continuously been adjusted downward from the historical peak in 4Q2018 until now, it may decline further to approach the demand-supply equilibrium, per the management. Considering all these factors, we revise up our 1-year target price by 25% for VHC to VND 38,100/share. With an expected cash dividend of VND 1,500/share, the total return is 16%, compared to the closing price as of May 21st, 2020. We recommend to ACCUMULATE this stock.
REE is currently in our conviction list with a pre-COVID-19 target price of VND 38,300. Its recent AGM has approved a conservative guidance for 2020 because the majority of its business segments have been and will continue to be impacted by the pandemic. REE targets a 23% revenue growth and a flat (-1.2%) income growth. Accordingly, the cash dividend for 2020 will remain at VND 1,600 per share (dividend yield 5.1%). Around a 30% payout ratio while retained earnings will fund REE’s renewable energy projects and the e.town 6 office tower.
Pork prices in 2Q are expected to remain high due to the shortage of domestic supply. Therefore, we think that DBC can still gain a lot of profit from the animal husbandry segment as in 1Q. Besides, re-herd activities are being strongly supported by the Government, so the demand for animal feed may increase in the near future. This will help the selling price and GPM of the animal feed segment to increase slightly compared to 1Q. Therefore, we expect both 2Q revenue and profit to be higher than 1Q results.
In 1Q2020, VPB maintained the highest PBT growth amongst banks on our watch list. For the next few quarters, we expect the pandemic impacts to lend more weight on the bank’s performance upon more obvious income slowdown and the escalation of provision booking. However, the timely and appropriate response to the virus situation, coupled with low leverage (asset leverage of 8.9x) and strong capital (CAR Basel II at 11.14%) should allow the bank to withstand the epidemic situation. Longer term, we expect that the overall growth outlook should remain positive when the pandemic impact is over, and VPB would still be able to achieve a higher growth than sector average.
The bank has sought shareholders’ approval for treasury shares purchase (up to 5%) and calling of USD300mn international bonds issued previously, which imply abundant liquidity. The plan of locking foreign room at 15%, if possible, would create room for a strategic placement. These are subjected to state agencies’ approval and actual market evolvement.
Considering the impacts of Covid-19 on the economy and VPB in particular, we reduce our 2020E earnings growth forecast to 10.9%, translating to 2020E ROE of 18.9%. We adjust the stock’s target price to VND28,000/share (8% lower than in our February report on VPB), equivalent to a 12% upside compared to the current market price. We thereby recommend to ACCUMULATE the stock.